The advantage of our pharmacological mGBM-TK implantation model is that we can investigate tumor regrowth from GBM cells escaping a tumor cell specific death paradigm without therapeutic interventions that would also involve the parenchyma. This evidence concerns the gene TKT and neoplasm.